NSCLC non-metastatic

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 13/08/2019)

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA NSCLC.

PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of  PDC*Lung01 Cancer Vaccine in NSCLC

New trial in start-up: currently no new trials